Chronic Obstructive Pulmonary Disease
Conditions
Keywords
Chronic obstructive pulmonary disease, Pulmonary rehabilitation, Telemedicine, Quality of life, Inspiratory muscle training, Test of incremental respiratory endurance
Brief summary
Subjects with chronic obstructive pulmonary disease (COPD) frequently develop considerable deterioration in exercise capacity in association with weakness and deconditioning of the respiratory muscles, which can be corrected with specific therapies. While pulmonary rehabilitation is a central component in the rather complex manangement of COPD, there is currently a lack of centers able to provide appropriate rehabilitation services in the Czech Republic. The main objective of this study will be to fully evaluate the utility of the Test of Incremental Respiratory Endurance (TIRE) as an at-home inspiratory muscle training method in subjects with COPD, while comparing the effectiveness of this novel training approach to the outcomes of more traditional ispiratory muscle training protocols. This prospective, randomized controlled trial will include 2 treatment groups and 1 sham intervention group in a 1:1:1 ratio. All participants will undergo a certain type of IMT regardless of group assignment, which will be perfomed via two different devices. The trial will comprise of an 8-week at-home training period with remote supervision followed by 4 months of unsupervised, independent inspiratory muscle training. Study outcomes will include measures of inspiratory muscle strength and endurance, pulmonary function, COPD-specific symptomatology, functional exercise capacity, surrogate markers of mortality risk, mental health status and health-related quality of life of participants. While investigators acknowledge the value of standard inspiratory muscle training protocols which use Threshold devices, investigators believe that the TIRE training has the potential to provide additional clinical benefits since it is able to modulate all aspects of muscular performance, including strength, endurance and work capacity. Investigators hypothesize that, as a home-based stand-alone rehabilitative therapy, TIRE will be superior to standard IMT in improving COPD-related measures.
Detailed description
Eligible participants will be randomly assigned to one of the following three distinct home-based IMT protocols: (1) TIRE, (2) Standard, and (3) Sham (i.e. Low Resistance). All subjects will undergo 8 weeks of daily unsupervised IMT using either a PrO2® device (Design Net, Smithfield, USA) or Threshold device at home. All training modalities require the subjects to be seated and wearing a nose clip while performing the required breaths. Subjects will be instructed on respective training procedures and complete first training session in the presence of a research team member upon enrollment. Regardless of training method, participants will be instructed to fill in diary cards at the end of each training session, in which participants document how many breaths were able to perform. This information will be later used for compliance assessment. Participants will be also provided with user guides developed by investigators research team with detailed instructions regarding equipment set-up, training protocol and contact information. In addition, subjects will receive weekly phone calls from week 0 to week 8 to encourage compliance and adherence to the study protocol, to address any subject questions or concerns, and to collect information regarding participants current symptomatology.
Interventions
The TIRE training regimen will involve the use of a tablet provided to assigned subjects with the training software installed and a PrO2® device through which they will train. The software allows subjects to track their inspiratory muscle performance via real-time graphic representations of their efforts as training progresses.
The Threshold incorporates a flow-independent one-way valve to ensure consistent resistance and features an adjustable specific pressure setting to be set based on MIP values of each subject.
The Threshold incorporates a flow-independent one-way valve to ensure consistent resistance and features an adjustable specific pressure setting to be set based on MIP values of each subject.
Sponsors
Study design
Eligibility
Inclusion criteria
* individuals over the age of 40 * clinical and functional diagnosis of COPD * Global Initiative of Chronic Obstructive Lung Disease (GOLD) - stages I to IV * evidence of inspiratory muscle weakness, defined as a MIP ≤ 80 cmH2O and a SMIP ≤ 427 PTU * ability to operate a computer, tablet or smartphone * clinical stability with no history of infections or exacerbation of respiratory symptoms for at least two months prior to study enrollment * non-participation in exercise programs in the past 12 months.
Exclusion criteria
* subjects with history of lung surgery, lung cancer, * any diagnosed cognitive (i.e. Mini Mental State Examination score \< 24), * orthopedic, neurological or neuromuscular disorders
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Sustained Maximal Inspiratory Pressure (SMIP) | Change from baseline to 8 weeks and 24 weeks | The primary outcome measure will be SMIP, which will be obtained along with MIP and ID in every subject using the PrO2® device, an electronic pressure manometer which utilizes wireless technology to connect to a tablet containing the software of the Test of Incremental Respiratory Endurance. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Maximal Inspiratory Pressure (MIP) | Change from baseline to 8 weeks and 24 weeks | MIP will be obtained from a maximal inspiratory effort from residual volume using the TIRE software and recorded in centimeters of water. |
| Inspiratory Duration (ID) | Change from baseline to 8 weeks and 24 weeks | ID will be obtained from a maximal and sustained inspiratory effort using the TIRE software and recorded in seconds. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Six-minute Walk Test (6MWT) | Change from baseline to 8 weeks and 24 weeks | Functional exercise capacity will be determined using the 6MWT. The best distance covered over a time of 6 minutes will be recorded in metres. |
| Modified Medical Research Council (mMRC) Dyspnea Scale | Change from baseline to 8 weeks and 24 weeks | This scale ranges from zero to four, with higher scores indicating a greater degree of breathlessness. |
| Hospital Anxiety and Depression scale (HADS) | Change from baseline to 8 weeks and 24 weeks | The questionnaire comprises seven questions for anxiety and seven questions for depression. Each item on the questionnaire is scored from 0-3 and this means that a person can score between 0 and 21 for either anxiety or depression. |
| Forced expiratory volume in the first second (FEV1) | Change from baseline to 8 weeks and 24 weeks | FEV1 will be obtained from pulmonary function tests which comprise post-bronchodilator spirometry using SpiroScout® and whole-body plethysmography using the PowerCube® Body |
| COPD Assessment Test (CAT) | Change from baseline to 8 weeks and 24 weeks | This instrument that can quantify the impact of COPD on the patient's health. The CAT has a scoring range of 0-40. Higher scores denote a more severe impact of COPD. |
| Satisfaction - self-completed questionnaire | Change from baseline to 8 weeks and 24 weeks | Subjects will be provided with a 5-item self-completed questionnaire developed by our research team that will measure their satisfaction with the intervention they received and the study in general. The items will be presented in the form of statements to which subjects will be asked to respond using a 1-5 Likert scale (strongly agree, agree, not sure, disagree, and strongly disagree). |
| St.George's Respiratory Questionnaire (SGRQ) | Change from baseline to 8 weeks and 24 weeks | The SGRQ is a 50-item questionnaire developed to measure health status (quality of life) in patients with diseases of airways obstruction. Scores range from 0 to 100, with higher scores indicating more limitations. |
| Inspiratory capacity (IC) | Change from baseline to 8 weeks and 24 weeks | IC will be obtained from pulmonary function tests which comprise post-bronchodilator spirometry using SpiroScout® and whole-body plethysmography using the PowerCube® Body |
| Forced vital capacity (FVC) | Change from baseline to 8 weeks and 24 weeks | FVC will be obtained from pulmonary function tests which comprise post-bronchodilator spirometry using SpiroScout® and whole-body plethysmography using the PowerCube® Body |
Countries
Czechia